Chronic Bronchitis Diagnosis Criteria: An In-Depth Guide for Healthcare Professionals

Introduction

Chronic bronchitis, a persistent inflammatory condition affecting the airways, is clinically defined by a chronic productive cough lasting for at least three months in each of two consecutive years, in the absence of other identifiable causes. In adults, this condition is most frequently attributed to prolonged exposure to irritants, with cigarette smoking being the predominant etiological factor. However, a significant number of cases arise from environmental and occupational exposures. Chronic bronchitis is characterized by excessive mucus production, leading to airway obstruction and inflammation. Patients typically present with a persistent cough, sputum production, and in more severe instances, shortness of breath, wheezing, and fatigue. While often considered a component of chronic obstructive pulmonary disease (COPD), chronic bronchitis can also manifest independently, increasing the risk of airflow limitation and subsequent decline in lung function. In pediatric populations, the term protracted bacterial bronchitis (PBB) is often used, characterized by persistent neutrophilic inflammation driven by bacterial infections. PBB is defined by a chronic wet cough lasting beyond four weeks that resolves following a two-week course of antibiotic therapy. Untreated PBB can progress to bronchiectasis and long-term lung impairment.

Understanding the Chronic Bronchitis Diagnosis Criteria is crucial for healthcare professionals to ensure accurate identification, appropriate management, and improved patient outcomes. This article provides a comprehensive overview of the diagnostic criteria, evaluation methods, and management strategies for chronic bronchitis in both adults and children, aiming to enhance the competence of healthcare providers in addressing this prevalent condition.

Etiology and Risk Factors Influencing Diagnosis

Establishing the diagnosis of chronic bronchitis necessitates understanding its diverse etiologies. Prolonged exposure to lung irritants is the primary driver, with smoking being the most significant. It’s crucial to recognize that a considerable proportion of chronic bronchitis cases occur in individuals who have never smoked, highlighting the importance of considering other environmental and occupational factors. Exposure to mineral dust, gases, fumes, and solvents are established non-smoking related causes. Furthermore, the use of biomass fuels, particularly in developing countries, represents a significant risk factor, especially for women exposed during cooking.

Genetic predisposition also plays a role in susceptibility to chronic bronchitis. Research has identified specific genetic markers associated with mucus hypersecretion and COPD, underscoring the complex interplay of genetics and environmental factors. Additional risk factors that contribute to the development of chronic bronchitis and should be considered in the diagnostic process include air pollution, pre-existing asthma, gastroesophageal reflux disease (GERD), recurrent respiratory infections, chronic aspiration, and allergies.

In children, the etiology of protracted bacterial bronchitis (PBB) differs. PBB is primarily attributed to chronic infection with bacteria such as Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Impaired mucociliary clearance and airway malacia are underlying factors that predispose children to these persistent bacterial infections. Understanding these distinct etiologies is essential for applying the appropriate chronic bronchitis diagnosis criteria across different age groups.

Epidemiology: Prevalence and Demographics Relevant to Diagnosis

Epidemiological data provides crucial context for the diagnosis of chronic bronchitis. While chronic bronchitis is a common cause of chronic cough, its true incidence is often underestimated as many smokers do not seek medical attention for their cough. Studies indicate that chronic bronchitis affects a significant portion of the global population, and a substantial percentage of individuals with COPD also exhibit chronic bronchitis.

In the United States, millions are affected, with prevalence peaking in middle age but also affecting younger adults. Demographic factors that increase the likelihood of chronic bronchitis diagnosis in adults include older age, female sex, asthma, obstructive sleep apnea, and specific racial/ethnic backgrounds.

For pediatric populations, PBB is the most common cause of chronic wet cough in children under 5 years old. PBB is more frequently diagnosed in male children and those attending childcare, with a history of prior chronic cough, household crowding, and homelessness also increasing risk. These epidemiological trends are important for healthcare providers to consider when evaluating patients and applying chronic bronchitis diagnosis criteria in different demographic groups.

Pathophysiology: Biological Mechanisms Underlying Diagnosis

The pathophysiology of chronic bronchitis provides insights into the clinical manifestations and diagnostic approaches. In adults, chronic exposure to irritants triggers a cascade of events leading to mucus overproduction and airway inflammation. Inflammatory mediators and humoral factors stimulate mucin release, aiming to protect the airway. However, this protective mechanism becomes maladaptive in chronic bronchitis, leading to goblet cell hyperplasia and excessive mucus secretion. Neutrophils and the epidermal growth factor receptor (EGFR) play key roles in this process.

Neutrophil-mediated elastase and reactive oxygen species contribute to mucus hypersecretion and airway inflammation. In healthy lungs, macrophages clear apoptotic neutrophils. In chronic bronchitis, impaired clearance leads to neutrophil necrosis, releasing elastase and reactive oxygen species into the sputum. These substances further activate EGFR, promoting mucin gene transcription and goblet cell degranulation, exacerbating mucus production.

Mucin concentration is a critical factor in the pathophysiology. Increased levels of mucins, particularly MUC5B and MUC5AC, contribute to faulty mucus transport and accumulation in the airways. This mucus accumulation, combined with epithelial thickening, obstructs airflow and predisposes airways to collapse. The resulting impaired mucus clearance leads to recurrent infections and further inflammation. Understanding these pathophysiological processes is essential for interpreting clinical findings and applying chronic bronchitis diagnosis criteria effectively.

In children with PBB, initial respiratory insults, often viral infections, compromise lung defenses, leading to mucus overproduction and bacterial overgrowth, frequently within biofilms. Biofilms protect bacteria from antibiotics, necessitating prolonged treatment durations. Environmental and genetic factors further contribute to the pathogenesis of PBB.

Histopathology: Microscopic Features Supporting Diagnosis

Histopathological findings can support the diagnosis of chronic bronchitis, although they are not typically required for routine clinical diagnosis. Gross examination reveals a boggy mucosa with excessive mucus and pus. Microscopic analysis in early chronic bronchitis demonstrates mucus hypersecretion in large airways and submucosal gland hypertrophy in the trachea and bronchi. As the condition progresses, goblet cell hyperplasia extends to smaller airways, accompanied by dysplasia and squamous metaplasia. The Reid index, quantifying submucosal gland enlargement, is elevated in chronic bronchitis. While histopathology is more relevant in research settings, understanding these features provides a deeper appreciation of the structural changes associated with chronic bronchitis.

History and Physical Examination: Core Components of Diagnosis

A thorough history and physical examination are foundational to establishing the diagnosis of chronic bronchitis.

Clinical Features in Adults:

The hallmark symptom is a persistent productive cough. Inquire about the duration and characteristics of the cough, sputum production (color, volume, consistency), and associated symptoms like dyspnea, wheezing, and chest tightness. Patients may also report fatigue, weight changes, syncope, and symptoms of depression or anxiety. Sputum is typically clear or white, but purulent sputum may suggest acute infection. It is important to ascertain the patient’s smoking history, occupational and environmental exposures, and history of respiratory illnesses.

Physical examination findings in mild chronic bronchitis may be subtle, such as faint wheezing or a prolonged expiratory phase. Moderate to severe disease may present with signs of hyperinflation (increased resonance to percussion, decreased breath sounds) and basilar crackles. End-stage COPD with chronic bronchitis may exhibit accessory muscle use, Hoover sign, pursed-lip breathing, cyanosis, and signs of right heart failure. Digital clubbing is not typical of COPD and should prompt consideration of alternative diagnoses. During acute exacerbations, increased cough, sputum production, dyspnea, tachycardia, and tachypnea are common.

Clinical Features in Children:

In children, the key symptom is a persistent wet cough lasting at least four weeks, suggestive of PBB. Typically, there are no signs of upper respiratory infection or chronic lung disease (no digital clubbing or chest wall deformity). Wheezing may be reported by parents but is not consistently auscultated. Coarse breath sounds or crackles are more common findings on chest auscultation. Detailed history should include birth history, family history of respiratory diseases, childcare attendance, and history of recurrent respiratory infections.

Evaluation and Diagnostic Studies: Confirming the Diagnosis

The diagnosis of chronic bronchitis relies primarily on clinical criteria, but investigations may be necessary to exclude other conditions and assess disease severity.

Initial evaluation should include a detailed history and physical examination as described above. Further investigations are guided by clinical findings and risk factors.

Diagnostic Studies:

Chest Radiograph: Recommended for adults with cough exceeding 8 weeks and children with cough over 4 weeks (except in specific cases like asthma or upper airway cough syndrome). Chest X-ray helps rule out other pulmonary pathologies. In PBB, chest radiography may be normal or show peribronchial accentuation.
Computed Tomography (CT) of the Chest: Indicated if chest radiograph is abnormal or if there is high suspicion for conditions like lung cancer, even with a normal chest radiograph. CT provides detailed anatomical information and can identify bronchiectasis or other structural lung diseases.
Pulmonary Function Tests (PFTs): Essential to assess for airflow obstruction and diagnose COPD. PFTs, including pre- and post-bronchodilator measurements, are recommended for adults and children over 3 years old with chronic respiratory symptoms. While chronic bronchitis can exist without airflow obstruction, PFTs are crucial to assess for COPD and asthma.
Sputum Culture and Bronchoscopy with Bronchoalveolar Lavage (BAL): Generally not required for routine diagnosis of chronic bronchitis or PBB. Bronchoscopy with BAL and cultures may be considered in children with prolonged cough unresponsive to initial antibiotic treatment or with atypical features, to guide antibiotic selection and rule out other conditions. In adults, sputum culture is typically reserved for suspected bacterial exacerbations.

Protracted Bacterial Bronchitis (PBB) Diagnostic Criteria:

The diagnosis of PBB is primarily clinical and based on the following criteria:

Chronic wet cough for at least 4 weeks.
Exclusion of alternative diagnoses through evaluation (including normal spirometry and chest radiography, though peribronchial accentuation is acceptable).
Absence of signs or symptoms suggestive of other diagnoses.
Cough resolution following a 2-week course of appropriate antibiotics.

In cases of recurrent PBB (more than 3 episodes per year), further evaluation for underlying predisposing conditions is warranted, including bronchoscopy with BAL, high-resolution CT scan, sweat test (to rule out cystic fibrosis), and immune system evaluation.

Differential Diagnosis: Distinguishing Chronic Bronchitis from Other Conditions

A comprehensive differential diagnosis is crucial when evaluating patients with chronic cough and suspected chronic bronchitis. Conditions to consider include:

Respiratory Infections: Acute bronchitis, acute sinusitis, bacterial pharyngitis, influenza, pertussis, pneumonia, post-infectious cough, chronic sinusitis, tuberculosis, endemic fungal and parasitic infections.
Airway Diseases: Asthma, bronchiectasis, bronchiolitis, bronchomalacia, chronic suppurative lung disease, COPD, diffuse panbronchiolitis, primary ciliary dyskinesia, tracheomalacia.
Gastrointestinal Conditions: Gastroesophageal reflux disease (GERD).
Cardiac Conditions: Heart failure (can present with chronic cough and dyspnea).
Other Conditions: Alpha-1 antitrypsin deficiency, cystic fibrosis, immunodeficiency, lung cancer, medication effects (ACE inhibitors), obstruction or anatomic airway abnormality, obstructive sleep apnea, pulmonary fibrosis, upper airway cough syndrome (UACS).

Careful history, physical examination, and appropriate investigations help differentiate chronic bronchitis from these other conditions and establish an accurate chronic bronchitis diagnosis.

Treatment and Management: Addressing Chronic Bronchitis Post-Diagnosis

Effective management of chronic bronchitis is crucial to mitigate symptoms, prevent exacerbations, and improve long-term respiratory health. The primary goals are to reduce mucus production, enhance mucus clearance, minimize inflammation, and support effective cough mechanisms.

Chronic Bronchitis Management Strategies:

Smoking Cessation and Avoidance of Irritants: The cornerstone of treatment. Counseling, support groups, and pharmacotherapy should be offered to smokers. Avoidance of secondhand smoke, occupational and environmental irritants is equally important.
Pharmacological Interventions:
- Bronchodilators: Short-acting beta-agonists (e.g., albuterol) are used for symptom relief during exacerbations. Anticholinergic bronchodilators (e.g., ipratropium) may be added.
- Systemic Corticosteroids: Used for acute exacerbations of moderate to severe chronic bronchitis.
- Antibiotics: Indicated for acute exacerbations when there are increased dyspnea, sputum volume, and sputum purulence. Antibiotic choice depends on patient risk factors and local resistance patterns. Duration is typically 5 days.
- Mucolytics: Guidelines vary on routine use. Some guidelines suggest mucolytics (e.g., N-acetylcysteine, carbocysteine) may be considered for reducing exacerbation frequency in some patients, while others do not recommend them for stable chronic bronchitis.
- Phosphodiesterase-4 (PDE-4) Inhibitors: Roflumilast may be considered in patients with severe COPD and chronic bronchitis with a history of exacerbations to reduce inflammation.
Non-Pharmacological Interventions:
- Pulmonary Rehabilitation: Essential component, including supervised exercise training, self-management education, and psychosocial support. Improves exercise tolerance, reduces dyspnea, and enhances quality of life.
- Patient Education: Crucial for self-management, inhaler technique, recognizing exacerbation symptoms, and medication adherence.
Vaccinations: Annual influenza vaccine, pneumococcal vaccines (PCV21, PCV20, or PCV15 followed by PPSV23), COVID-19 vaccine, Tdap, RSV vaccine (for older adults), and herpes zoster vaccine (for older adults) are recommended for patients with chronic lung disease.

Protracted Bacterial Bronchitis (PBB) Management:

Antibiotics: Minimum 2 weeks of antibiotic therapy, often amoxicillin-clavulanate. Alternatives include second- or third-generation cephalosporins, trimethoprim-sulfamethoxazole, or macrolides (excluding azithromycin due to resistance concerns). Longer courses (4-6 weeks) may be used based on guidelines and symptom resolution.
Further Evaluation for Recurrent PBB: Children with more than 3 episodes per year require evaluation for underlying conditions like bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or immunodeficiency.

Prognosis and Complications: Long-Term Implications of Chronic Bronchitis

Chronic bronchitis has significant long-term implications. It is associated with worsened airflow obstruction, accelerated lung function decline, increased risk of COPD development, and higher all-cause mortality, particularly in younger individuals. Systemic inflammation is thought to contribute to increased mortality risk. Prognosis is influenced by disease severity, age, smoking history, genetics, comorbidities, and access to healthcare.

Potential Complications of Chronic Bronchitis:

Worsening lung function and COPD development
Increased risk of respiratory infections
Anxiety and depression
Pulmonary hypertension and cor pulmonale
Increased risk of cardiac disease
Bronchiectasis
Osteoporosis (related to immobility and corticosteroid use)
Pneumothorax
Polycythemia
Death

Early diagnosis of chronic bronchitis and proactive management are crucial to mitigate these risks and improve patient outcomes. For PBB in children, the prognosis is generally good with appropriate treatment, but untreated PBB can lead to bronchiectasis and long-term lung impairment.

Deterrence and Patient Education: Empowering Patients for Better Outcomes

Deterrence and patient education are vital components of chronic bronchitis management. Clinicians should emphasize smoking cessation, avoidance of environmental irritants, and the importance of a healthy lifestyle. Patient education should cover:

Risks associated with smoking and environmental exposures
Importance of medication adherence and proper inhaler technique
Recognition of exacerbation symptoms and seeking timely medical care
Benefits of pulmonary rehabilitation
Vaccination recommendations
Lifestyle modifications: balanced diet, regular exercise, hydration

Empowering patients with knowledge and self-management strategies is crucial to improve adherence, reduce disease progression, and enhance quality of life. Early diagnosis and comprehensive patient education are key to promoting long-term lung health in individuals with chronic bronchitis.

Enhancing Healthcare Team Outcomes: An Interprofessional Approach

Optimal management of chronic bronchitis necessitates a collaborative, interprofessional team approach. This team may include pulmonary specialists, primary care clinicians, nurses, respiratory therapists, pharmacists, physical therapists, dieticians, and potentially cardiologists and emergency medicine physicians. Each team member contributes unique expertise to provide comprehensive, patient-centered care.

Effective interprofessional communication and care coordination are essential for:

Accurate diagnosis of chronic bronchitis
Developing individualized treatment plans
Ensuring seamless implementation of treatment strategies
Managing comorbidities
Reducing hospitalizations
Preventing disease progression
Improving quality of life
Prompt management of acute exacerbations

By fostering collaboration and leveraging the skills of each team member, healthcare professionals can optimize patient outcomes and enhance team performance in the management of chronic bronchitis.

Review Questions

(Please note: Review questions from the original article are not included in this rewritten version as per instructions.)

References

(References from the original article are retained to maintain accuracy and provide source material. The format is kept consistent with the original.)

1.Zhang J, Wurzel DF, Perret JL, Lodge CJ, Walters EH, Dharmage SC. Chronic Bronchitis in Children and Adults: Definitions, Pathophysiology, Prevalence, Risk Factors, and Consequences. J Clin Med. 2024 Apr 20;13(8) [PMC free article: PMC11051495] [PubMed: 38673686]

2.Feng W, Zhang Z, Liu Y, Li Z, Guo W, Huang F, Zhang J, Chen A, Ou C, Zhang K, Chen M. Association of Chronic Respiratory Symptoms With Incident Cardiovascular Disease and All-Cause Mortality: Findings From the Coronary Artery Risk Development in Young Adults Study. Chest. 2022 Apr;161(4):1036-1045. [PMC free article: PMC9248281] [PubMed: 34740593]

3.Mejza F, Gnatiuc L, Buist AS, Vollmer WM, Lamprecht B, Obaseki DO, Nastalek P, Nizankowska-Mogilnicka E, Burney PGJ., BOLD collaborators. BOLD study collaborators. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. Eur Respir J. 2017 Nov;50(5) [PMC free article: PMC5699921] [PubMed: 29167298]

4.Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin DP, Hansel NN, Wise RA. Chronic productive cough is associated with death in smokers with early COPD. COPD. 2014 Aug;11(4):451-8. [PMC free article: PMC5120399] [PubMed: 24127996]

5.Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax. 1990 Aug;45(8):579-85. [PMC free article: PMC462624] [PubMed: 2402719]

6.de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007 Jan 01;175(1):32-9. [PubMed: 17008642]

7.Chang AB, Oppenheimer JJ, Irwin RS., CHEST Expert Cough Panel. Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2020 Jul;158(1):303-329. [PubMed: 32179109]

8.Marchant JM, Petsky HL, Morris PS, Chang AB. Antibiotics for prolonged wet cough in children. Cochrane Database Syst Rev. 2018 Jul 31;7(7):CD004822. [PMC free article: PMC6513288] [PubMed: 30062732]

9.Shields MD, Bush A, Everard ML, McKenzie S, Primhak R., British Thoracic Society Cough Guideline Group. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax. 2008 Apr;63 Suppl 3:iii1-iii15. [PubMed: 17905822]

10.Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006 Oct;130(4):1129-37. [PubMed: 17035447]

11.Dijkstra AE, de Jong K, Boezen HM, Kromhout H, Vermeulen R, Groen HJ, Postma DS, Vonk JM. Risk factors for chronic mucus hypersecretion in individuals with and without COPD: influence of smoking and job exposure on CMH. Occup Environ Med. 2014 May;71(5):346-52. [PubMed: 24642640]

12.Rodríguez E, Ferrer J, Zock JP, Serra I, Antó JM, de Batlle J, Kromhout H, Vermeulen R, Donaire-González D, Benet M, Balcells E, Monsó E, Gayete A, Garcia-Aymerich J., PAC-COPD Study Group. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One. 2014;9(2):e88426. [PMC free article: PMC3916435] [PubMed: 24516659]

13.Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. Chronic Obstr Pulm Dis. 2014 May 06;1(1):23-32. [PMC free article: PMC5559138] [PubMed: 28848808]

14.Lee JH, Cho MH, Hersh CP, McDonald ML, Crapo JD, Bakke PS, Gulsvik A, Comellas AP, Wendt CH, Lomas DA, Kim V, Silverman EK., COPDGene and ECLIPSE Investigators. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respir Res. 2014 Sep 21;15(1):113. [PMC free article: PMC4190389] [PubMed: 25241909]

15.Casara A, Turato G, Marin-Oto M, Semenzato U, Biondini D, Tinè M, Bernardinello N, Cocconcelli E, Cubero P, Balestro E, Spagnolo P, Marin JM, Cosio MG, Saetta M, Bazzan E. Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD). J Clin Med. 2022 Aug 20;11(16) [PMC free article: PMC9410001] [PubMed: 36013126]

16.Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009 Jul;4(3):115-23. [PMC free article: PMC2714564] [PubMed: 19641641]

17.Ishak A, Everard ML. Persistent and Recurrent Bacterial Bronchitis-A Paradigm Shift in Our Understanding of Chronic Respiratory Disease. Front Pediatr. 2017;5:19. [PMC free article: PMC5309219] [PubMed: 28261574]

18.Gallucci M, Pedretti M, Giannetti A, di Palmo E, Bertelli L, Pession A, Ricci G. When the Cough Does Not Improve: A Review on Protracted Bacterial Bronchitis in Children. Front Pediatr. 2020;8:433. [PMC free article: PMC7426454] [PubMed: 32850546]

19.Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis. 1990 Mar;141(3):640-7. [PubMed: 2178528]

20.Kim V, Criner GJ. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. Curr Opin Pulm Med. 2015 Mar;21(2):133-41. [PMC free article: PMC4373868] [PubMed: 25575367]

21.Dharmage SC, Perret JL, Burgess JA, Lodge CJ, Johns DP, Thomas PS, Giles GG, Hopper JL, Abramson MJ, Walters EH, Matheson MC. Current asthma contributes as much as smoking to chronic bronchitis in middle age: a prospective population-based study. Int J Chron Obstruct Pulmon Dis. 2016;11:1911-20. [PMC free article: PMC4993278] [PubMed: 27574415]

22.Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Feb 01;187(3):228-37. [PMC free article: PMC4951627] [PubMed: 23204254]

23.Senaratna CV, English DR, Currier D, Perret JL, Lowe A, Lodge C, Russell M, Sahabandu S, Matheson MC, Hamilton GS, Dharmage SC. Sleep apnoea in Australian men: disease burden, co-morbidities, and correlates from the Australian longitudinal study on male health. BMC Public Health. 2016 Oct 31;16(Suppl 3):1029. [PMC free article: PMC5103243] [PubMed: 28185594]

24.Wurzel DF, Marchant JM, Yerkovich ST, Upham JW, Mackay IM, Masters IB, Chang AB. Prospective characterization of protracted bacterial bronchitis in children. Chest. 2014 Jun;145(6):1271-1278. [PMC free article: PMC7173205] [PubMed: 24435356]

25.O’Grady KF, Mahon J, Arnold D, Grimwood K, Hall KK, Goyal V, Marchant JM, Phillips N, Acworth J, King A, Scott M, Chang AB. Predictors of the Development of Protracted Bacterial Bronchitis following Presentation to Healthcare for an Acute Respiratory Illness with Cough: Analysis of Three Cohort Studies. J Clin Med. 2021 Dec 07;10(24) [PMC free article: PMC8707704] [PubMed: 34945030]

26.Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res. 2001;2(2):85-9. [PMC free article: PMC59573] [PubMed: 11686870]

27.Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med. 2004;3(3):147-59. [PubMed: 15219174]

28.Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez F, Paine R, Woodruff PG, O’Neal WK, Boucher RC. Airway Mucin Concentration as a Marker of Chronic Bronchitis. N Engl J Med. 2017 Sep 07;377(10):911-922. [PMC free article: PMC5706541] [PubMed: 28877023]

29.Radicioni G, Ceppe A, Ford AA, Alexis NE, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez FJ, Ozkan E, Paine R, Woodruff PG, O’Neal WK, Boucher RC, Kesimer M. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2021 Nov;9(11):1241-1254. [PMC free article: PMC8570975] [PubMed: 34058148]

30.Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009 Oct;64(10):894-900. [PMC free article: PMC4706745] [PubMed: 19581277]

31.Craven V, Everard ML. Protracted bacterial bronchitis: reinventing an old disease. Arch Dis Child. 2013 Jan;98(1):72-6. [PubMed: 23175647]

32.Imran S, Shan M, Muazam S. A Comparative Histological Study of Submucosal Gland Hypertrophy in Trachea of Mice Exposed to Cigarette and Shisha Smoke. J Coll Physicians Surg Pak. 2018 Mar;28(3):192-195. [PubMed: 29544574]

33.Badgett RG, Tanaka DJ, Hunt DK, Jelley MJ, Feinberg LE, Steiner JF, Petty TL. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med. 1993 Feb;94(2):188-96. [PubMed: 8430714]

34.Lemyze M, Bart F. Hoover sign. CMAJ. 2011 Feb 08;183(2):E133. [PMC free article: PMC3033956] [PubMed: 21149523]

35.Chang AB, Oppenheimer JJ, Weinberger MM, Rubin BK, Grant CC, Weir K, Irwin RS., CHEST Expert Cough Panel. Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report. Chest. 2017 Apr;151(4):884-890. [PubMed: 28143696]

36.Chang AB, Upham JW, Masters IB, Redding GR, Gibson PG, Marchant JM, Grimwood K. Protracted bacterial bronchitis: The last decade and the road ahead. Pediatr Pulmonol. 2016 Mar;51(3):225-42. [PMC free article: PMC7167774] [PubMed: 26636654]

37.Chang AB, Oppenheimer JJ, Weinberger M, Rubin BK, Irwin RS. Children With Chronic Wet or Productive Cough–Treatment and Investigations: A Systematic Review. Chest. 2016 Jan;149(1):120-42. [PubMed: 26757284]

38.Mullen JB, Wright JL, Wiggs BR, Paré PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax. 1987 Nov;42(11):843-8. [PMC free article: PMC461007] [PubMed: 3424265]

39.Malesker MA, Callahan-Lyon P, Madison JM, Ireland B, Irwin RS., CHEST Expert Cough Panel. Chronic Cough Due to Stable Chronic Bronchitis: CHEST Expert Panel Report. Chest. 2020 Aug;158(2):705-718. [PubMed: 32105719]

40.Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians. Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-827. [PubMed: 33819054]

41.Llor C, Moragas A, Miravitlles M, Mesquita P, Cordoba G. Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. Pulm Pharmacol Ther. 2022 Feb;72:102111. [PubMed: 35032637]

42.Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology–impact on approaches to risk stratification and therapy. Infect Dis Clin North Am. 2004 Dec;18(4):861-82, ix. [PubMed: 15555829]

43.Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, Monsó E, Montón C. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014 Jun 26;14:103. [PMC free article: PMC4094400] [PubMed: 24964956]

44.Sethi S, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Wilson R. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection. 2016 Feb;44(1):65-76. [PMC free article: PMC4735236] [PubMed: 26370552]

45.Daubin C, Valette X, Thiollière F, Mira JP, Hazera P, Annane D, Labbe V, Floccard B, Fournel F, Terzi N, Du Cheyron D, Parienti JJ., BPCTrea Study Group. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med. 2018 Apr;44(4):428-437. [PMC free article: PMC5924665] [PubMed: 29663044]

46.Kuijpers SME, Buis DTP, Ziesemer KA, van Hest RM, Schade RP, Sigaloff KCE, Prins JM. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review. Lancet Infect Dis. 2025 Jan;25(1):94-113. [PubMed: 39243792]

47.Blackstock FC, Lareau SC, Nici L, ZuWallack R, Bourbeau J, Buckley M, Durning SJ, Effing TW, Egbert E, Goldstein RS, Kelly W, Lee A, Meek PM, Singh S., American Thoracic Society, Thoracic Society of Australia and New Zealand, Canadian Thoracic Society, and British Thoracic Society. Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation. An Official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report. Ann Am Thorac Soc. 2018 Jul;15(7):769-784. [PubMed: 29957038]

48.Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255-3262. [PMC free article: PMC5680946] [PubMed: 29138554]

49.Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, Moro P, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023 Sep 08;72(3):1-39. [PMC free article: PMC10495181] [PubMed: 37669242]

50.Boesing M, Albrich W, Bridevaux PO, Charbonnier F, Clarenbach C, Fellrath JM, Gianella P, Kern L, Latshang T, Pavlov N, Osthoff M, Steurer-Stey C, von Garnier C, Leuppi JD. Vaccination in adult patients with chronic lung diseases. Praxis (Bern 1994). 2024 Dec;113(11-12):297-305. [PubMed: 39697155]

51.Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, Schechter R, Poehling KA, Long SS, Loehr J, Cohen AL. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Sep 12;73(36):793-798. [PMC free article: PMC11392227] [PubMed: 39264843]

52.Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024 Aug 29;73(5):1-25. [PMC free article: PMC11501009] [PubMed: 39197095]

53.Chang AB, Oppenheimer JJ, Weinberger M, Weir K, Rubin BK, Irwin RS. Use of Management Pathways or Algorithms in Children With Chronic Cough: Systematic Reviews. Chest. 2016 Jan;149(1):106-19. [PubMed: 26356242]

54.Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Hilton Boon M, Kantar A, Lai K, McGarvey L, Rigau D, Satia I, Smith J, Song WJ, Tonia T, van den Berg JWK, van Manen MJG, Zacharasiewicz A. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020 Jan;55(1) [PMC free article: PMC6942543] [PubMed: 31515408]

55.Chang AB, Oppenheimer JJ, Weinberger M, Grant CC, Rubin BK, Irwin RS., CHEST Expert Cough Panel. Etiologies of Chronic Cough in Pediatric Cohorts: CHEST Guideline and Expert Panel Report. Chest. 2017 Sep;152(3):607-617. [PMC free article: PMC6026225] [PubMed: 28645463]

56.Valipour A, Fernandez-Bussy S, Ing AJ, Steinfort DP, Snell GI, Williamson JP, Saghaie T, Irving LB, Dabscheck EJ, Krimsky WS, Waldstreicher J. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020 Sep 01;202(5):681-689. [PMC free article: PMC7462406] [PubMed: 32407638]

57.Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB., NOTUS Study Investigators. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 Jun 27;390(24):2274-2283. [PubMed: 38767614]

58.Dotan Y, So JY, Kim V. Chronic Bronchitis: Where Are We Now? Chronic Obstr Pulm Dis. 2019 Apr 09;6(2):178-192. [PMC free article: PMC6596437] [PubMed: 31063274]

59.Pelkonen MK, Notkola IK, Laatikainen TK, Jousilahti P. Chronic bronchitis in relation to hospitalization and mortality over three decades. Respir Med. 2017 Feb;123:87-93. [PubMed: 28137502]

60.Wiltingh H, Marchant JM, Goyal V. Cough in Protracted Bacterial Bronchitis and Bronchiectasis. J Clin Med. 2024 Jun 04;13(11) [PMC free article: PMC11172502] [PubMed: 38893016]

61.Ruffles TJC, Marchant JM, Masters IB, Yerkovich ST, Wurzel DF, Gibson PG, Busch G, Baines KJ, Simpson JL, Smith-Vaughan HC, Pizzutto SJ, Buntain HM, Hodge G, Hodge S, Upham JW, Chang AB. Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study. Respirology. 2021 Mar;26(3):241-248. [PubMed: 33045125]

62.Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):104S-115S.